| Dr Praveen George, MD | |
|
16295 Willow Creek Rd, Lewes, DE 19958-3614 | |
| (302) 644-0999 | |
| Not Available |
| Full Name | Dr Praveen George |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 10 Years |
| Location | 16295 Willow Creek Rd, Lewes, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285052605 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beebe Medical Center | Lewes, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinic By The Sea Llc | 0840379608 | 7 |
| Beebe Medical Center Inc | 8921917972 | 31 |
News Archive
Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.
To investigate the immune memory sustainability of SARS-CoV-2-specific B cells and T cells, stimulated by the inactivated vaccine, and the potential need for a third booster dose in healthcare workers (HCWs), a non-randomized trial was undertaken by researchers at Sun Yat-sen University in Guangzhou, China. the research is posted online on the medRxiv* preprint server.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Oncology nurses in the outpatient setting face constant challenges in the management of patient care, as many cancer patients receive therapies known to cause allergic reactions or hypersensitivity. When such emergencies arise, oncology nurses need to quickly, competently and safely manage these specific needs. In order to address such a scenario, nurses at The Cancer Institute of New Jersey (CINJ) have developed a teaching method to make mock situations more closely resemble real emergency events.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
› Verified 9 days ago
| Entity Name | Beebe Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821196486 PECOS PAC ID: 8921917972 Enrollment ID: O20050112000653 |
News Archive
Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.
To investigate the immune memory sustainability of SARS-CoV-2-specific B cells and T cells, stimulated by the inactivated vaccine, and the potential need for a third booster dose in healthcare workers (HCWs), a non-randomized trial was undertaken by researchers at Sun Yat-sen University in Guangzhou, China. the research is posted online on the medRxiv* preprint server.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Oncology nurses in the outpatient setting face constant challenges in the management of patient care, as many cancer patients receive therapies known to cause allergic reactions or hypersensitivity. When such emergencies arise, oncology nurses need to quickly, competently and safely manage these specific needs. In order to address such a scenario, nurses at The Cancer Institute of New Jersey (CINJ) have developed a teaching method to make mock situations more closely resemble real emergency events.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
› Verified 9 days ago
| Entity Name | Clinic By The Sea Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477561306 PECOS PAC ID: 0840379608 Enrollment ID: O20080505000547 |
News Archive
Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.
To investigate the immune memory sustainability of SARS-CoV-2-specific B cells and T cells, stimulated by the inactivated vaccine, and the potential need for a third booster dose in healthcare workers (HCWs), a non-randomized trial was undertaken by researchers at Sun Yat-sen University in Guangzhou, China. the research is posted online on the medRxiv* preprint server.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Oncology nurses in the outpatient setting face constant challenges in the management of patient care, as many cancer patients receive therapies known to cause allergic reactions or hypersensitivity. When such emergencies arise, oncology nurses need to quickly, competently and safely manage these specific needs. In order to address such a scenario, nurses at The Cancer Institute of New Jersey (CINJ) have developed a teaching method to make mock situations more closely resemble real emergency events.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Praveen George, MD 308 Penn St, Baltimore, MD 21230-2207 Ph: () - | Dr Praveen George, MD 16295 Willow Creek Rd, Lewes, DE 19958-3614 Ph: (302) 644-0999 |
News Archive
Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.
To investigate the immune memory sustainability of SARS-CoV-2-specific B cells and T cells, stimulated by the inactivated vaccine, and the potential need for a third booster dose in healthcare workers (HCWs), a non-randomized trial was undertaken by researchers at Sun Yat-sen University in Guangzhou, China. the research is posted online on the medRxiv* preprint server.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Oncology nurses in the outpatient setting face constant challenges in the management of patient care, as many cancer patients receive therapies known to cause allergic reactions or hypersensitivity. When such emergencies arise, oncology nurses need to quickly, competently and safely manage these specific needs. In order to address such a scenario, nurses at The Cancer Institute of New Jersey (CINJ) have developed a teaching method to make mock situations more closely resemble real emergency events.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
› Verified 9 days ago
Dr. George M. Kluchnik, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 424 Savannah Rd, Lewes, DE 19958 Phone: 302-645-3555 Fax: 302-644-3560 | |
Amulya D Amirneni, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 17005 Old Orchard Rd, Lewes, DE 19958 Phone: 302-703-4025 | |
Dr. Steven A Calamita, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 424 Savannah Rd, Lewes, DE 19958 Phone: 302-645-3300 | |
Dr. Maneshkumar F. Patel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 400 Savannah Rd, Suite B, Lewes, DE 19958 Phone: 302-645-3555 | |
Robert C Deckmann, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 33663 Bayview Medical Dr, Unit 2, Lewes, DE 19958 Phone: 302-645-9325 Fax: 302-645-5214 | |
Harry J Anagnostakos, DO Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 400 Savannah Rd, Suite B, Lewes, DE 19958 Phone: 302-645-3555 Fax: 302-644-3560 | |
Dr. Carlton Boxhill, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1526 Savannah Rd, Lewes, DE 19958 Phone: 302-645-2244 Fax: 302-645-1173 |